PV-267

PV-267 is a highly selective, peptide-derived small molecule inhibitor of antigen binding and presentation by the multiple‑sclerosis–associated MHC class II allele HLA‑DR2b (HLA‑DRB1*15:01), developed by Provid Pharmaceuticals as a targeted immunomodulatory therapy for autoimmune diseases such as multiple sclerosis and anti‑GBM glomerulonephritis. By binding to the peptide‑binding groove of HLA‑DR2b with low‑nanomolar affinity and high selectivity over other HLA‑DR alleles, PV‑267 blocks loading and presentation of myelin and other autoantigenic peptides to CD4+ T cells, thereby inhibiting antigen‑specific cytokine production and T‑cell proliferation while largely sparing responses restricted by other MHC class II molecules.[1][4][7][9][10][11] In humanized HLA‑DR2b or HLA‑DR15 transgenic models, PV‑267 has demonstrated efficacy in both prevention and treatment of experimental autoimmune encephalomyelitis and in attenuating experimental autoimmune anti‑GBM glomerulonephritis, supporting its potential as an allele‑specific disease‑modifying therapy.[1][4][7]